Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 11/20 | 0.44 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL485687 | 0.98 | MRGPRX4 (0.45) | MRGPRX4HCRTR1SCN7AKCNH2SCN5A | |
| Formic Acid SCHEMBL27693250 | 0.97 | MRGPRX4 (0.43) | MRGPRX4HCRTR1SCN7AKCNH2SCN5A | |
| SCHEMBL485826 | 0.88 | MRGPRX4 (0.51) | MRGPRX4HCRTR1MAPTLMNAPOLB | |
| SCHEMBL485703 | 0.87 | MRGPRX4 (0.50) | MRGPRX4 | |
| SCHEMBL485668 | 0.85 | CXCR2 (0.47) | MRGPRX4HCRTR1SCN7AKCNH2SCN5A | |
| Formic Acid SCHEMBL27712981 | 0.84 | MRGPRX4 (0.48) | MRGPRX4 | |
| SCHEMBL485784 | 0.82 | CXCR2 (0.44) | MRGPRX4LMNA | |
| SCHEMBL485478 | 0.81 | CXCR2 (0.56) | HCRTR1FAAH | |
| SCHEMBL485695 | 0.81 | CXCR2 (0.56) | HCRTR1HCRTR2 | |
| SCHEMBL485706 | 0.81 | CXCR2 (0.44) | MRGPRX4LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836158-B1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION | SANOFI AVENTIS DEUTSCHLAND (DE) | 2012-02-01 | — | — | EP | claimed |